Search Results

Journey Medical Corporation announced it has entered into an exclusive license agreement with Maruho Co., Ltd., a Japanese company specializing in dermatology and also Journey’s exclusive licensing partner that developed and is commercializing Qbrexza in Japan.

Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into an expanded strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Greater China and additional key Asian countries.

Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced that it has entered into a license agreement with Maruho Co., Ltd. (“Maruho”), granting Maruho exclusive rights to market CANDINⓇ in Japan for the treatment of Verruca vulgaris (common warts).

Evommune, Inc., a biotechnology company discovering and developing new ways to treat immune-mediated inflammatory diseases, today announced that it has entered into a strategic collaboration with Maruho Co., Ltd., to exclusively develop and commercialize EVO756 in Japan.

AOBiome Therapeutics Inc. (“AOB”) announced today that is has entered into an exclusive license and development agreement with Maruho Co., Ltd., to develop and commercialize AOB’s topical biologic B244 (currently preparing for global Phase 3 clinical trials), a therapeutic treatment for dermatological indications including Atopic Dermatitis, for both appearance and pruritus (itch).

Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.

Rege Nephro CO., Ltd. (https://www.regenephro.co.jp/en) has announced that patient enrollment began in April for the second stage of its Phase II clinical trial of tamibarotene as a developmental product for the treatment of autosomal dominant polycystic kidney disease (ADPKD) under the code RN-014.